National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.

 Sunitinib (Sutent®) summary